Teva Pharmaceutical Industries annual shareholders’ equity
2007
2008
2009
2010
2011
2012
2013
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Teva Pharmaceutical Industries Shareholders’ Equity Growth & History (TEVA)
Teva Pharmaceutical Industries's shareholders’ equity was $7.91B for fiscal 2025.
View full Teva Pharmaceutical Industries company overviewTeva Pharmaceutical Industries annual shareholders’ equity history
| Fiscal year | Period ended | Shareholders’ equity | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $7.91B | $2.54B | +47.22% |
| 2024 | 2024-12-31 | $5.37B | −$2.13B | −28.42% |
| 2023 | 2023-12-31 | $7.51B | −$298.0M | −3.82% |
| 2022 | 2022-12-31 | $7.80B | −$2.47B | −24.07% |
| 2021 | 2021-12-31 | $10.28B | $252.0M | +2.51% |
| 2020 | 2020-12-31 | $10.03B | −$3.95B | −28.24% |
| 2019 | 2019-12-31 | $13.97B | −$735.0M | −5.00% |
| 2018 | 2018-12-31 | $14.71B | −$2.65B | −15.28% |
| 2017 | 2017-12-31 | $17.36B | −$15.98B | −47.93% |
| 2016 | 2016-12-31 | $33.34B | — | — |
| 2013 | 2013-12-31 | $22.57B | −$203.0M | −0.89% |
| 2012 | 2012-12-31 | $22.77B | $573.0M | +2.58% |
| 2011 | 2011-12-31 | $22.20B | $248.0M | +1.13% |
| 2010 | 2010-12-31 | $21.95B | $2.73B | +14.18% |
| 2009 | 2009-12-31 | $19.22B | $2.84B | +17.36% |
| 2008 | 2008-12-31 | $16.38B | $2.51B | +18.13% |
| 2007 | 2007-12-31 | $13.86B | — | — |
Teva Pharmaceutical Industries quarterly shareholders’ equity
Q4.08
Q1.09
Q2.09
Q3.09
Q4.09
Q1.10
Q2.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
As of Dec 31, 2014
As of Mar 31, 2015
As of Jun 30, 2015
As of Sep 30, 2015
As of Dec 31, 2015
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Shareholders’ equity | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $7.75B | $926.0M | +13.56% |
| Q1 2026 | 2026-03-31 | $8.23B | $1.97B | +31.40% |
| Q4 2025 | 2025-12-31 | $7.91B | $2.54B | +47.22% |
| Q3 2025 | 2025-09-30 | $7.25B | $1.19B | +19.54% |
| Q2 2025 | 2025-06-30 | $6.83B | $468.0M | +7.36% |
| Q1 2025 | 2025-03-31 | $6.26B | −$1.02B | −13.96% |
| Q4 2024 | 2024-12-31 | $5.37B | −$2.13B | −28.42% |
| Q3 2024 | 2024-09-30 | $6.07B | −$864.0M | −12.47% |
| Q2 2024 | 2024-06-30 | $6.36B | −$693.0M | −9.83% |
| Q1 2024 | 2024-03-31 | $7.28B | −$582.0M | −7.40% |
| Q4 2023 | 2023-12-31 | $7.51B | −$298.0M | −3.82% |
| Q3 2023 | 2023-09-30 | $6.93B | −$1.84B | −20.96% |
| Q2 2023 | 2023-06-30 | $7.05B | −$1.99B | −21.97% |
| Q1 2023 | 2023-03-31 | $7.86B | −$1.48B | −15.88% |
| Q4 2022 | 2022-12-31 | $7.80B | −$2.47B | −24.07% |
| Q3 2022 | 2022-09-30 | $8.77B | −$1.70B | −16.24% |
| Q2 2022 | 2022-06-30 | $9.04B | −$1.29B | −12.47% |
| Q1 2022 | 2022-03-31 | $9.34B | −$656.0M | −6.56% |
| Q4 2021 | 2021-12-31 | $10.28B | $252.0M | +2.51% |
| Q3 2021 | 2021-09-30 | $10.47B | $874.0M | +9.11% |
| Q2 2021 | 2021-06-30 | $10.32B | −$3.53B | −25.47% |
| Q1 2021 | 2021-03-31 | $10.00B | −$3.53B | −26.10% |
| Q4 2020 | 2020-12-31 | $10.03B | −$3.95B | −28.24% |
| Q3 2020 | 2020-09-30 | $9.59B | −$4.20B | −30.44% |
| Q2 2020 | 2020-06-30 | $13.85B | −$270.0M | −1.91% |
| Q1 2020 | 2020-03-31 | $13.53B | −$1.20B | −8.15% |
| Q4 2019 | 2019-12-31 | $13.97B | −$735.0M | −5.00% |
| Q3 2019 | 2019-09-30 | $13.79B | −$3.94B | −22.22% |
| Q2 2019 | 2019-06-30 | $14.12B | −$3.82B | −21.27% |
| Q1 2019 | 2019-03-31 | $14.73B | −$3.89B | −20.89% |
| Q4 2018 | 2018-12-31 | $14.71B | −$2.65B | −15.28% |
| Q3 2018 | 2018-09-30 | $17.73B | −$10.94B | −38.16% |
| Q2 2018 | 2018-06-30 | $17.94B | −$10.06B | −35.92% |
| Q1 2018 | 2018-03-31 | $18.62B | −$15.40B | −45.27% |
| Q4 2017 | 2017-12-31 | $17.36B | −$15.98B | −47.93% |
| Q3 2017 | 2017-09-30 | $28.67B | −$6.46B | −18.38% |
| Q2 2017 | 2017-06-30 | $27.99B | −$2.16B | −7.15% |
| Q1 2017 | 2017-03-31 | $34.02B | $3.59B | +11.79% |
| Q4 2016 | 2016-12-31 | $33.34B | $3.57B | +11.99% |
| Q3 2016 | 2016-09-30 | $35.13B | $12.39B | +54.49% |
| Q2 2016 | 2016-06-30 | $30.15B | $7.11B | +30.87% |
| Q1 2016 | 2016-03-31 | $30.43B | $7.80B | +34.45% |
| As of Dec 31, 2015 | 2015-12-31 | $29.77B | $6.46B | +27.69% |
| As of Sep 30, 2015 | 2015-09-30 | $22.74B | −$894.0M | −3.78% |
| As of Jun 30, 2015 | 2015-06-30 | $23.04B | −$502.0M | −2.13% |
| As of Mar 31, 2015 | 2015-03-31 | $22.64B | −$331.0M | −1.44% |
| As of Dec 31, 2014 | 2014-12-31 | $23.31B | $748.0M | +3.31% |
| Q3 2014 | 2014-09-30 | $23.63B | $1.32B | +5.94% |
| Q2 2014 | 2014-06-30 | $23.54B | $2.02B | +9.41% |
| Q1 2014 | 2014-03-31 | $22.97B | $253.0M | +1.11% |
| Q4 2013 | 2013-12-31 | $22.57B | −$203.0M | −0.89% |
| Q3 2013 | 2013-09-30 | $22.31B | −$626.0M | −2.73% |
| Q2 2013 | 2013-06-30 | $21.52B | −$1.24B | −5.43% |
| Q1 2013 | 2013-03-31 | $22.71B | −$337.0M | −1.46% |
| Q4 2012 | 2012-12-31 | $22.77B | $573.0M | +2.58% |
| Q3 2012 | 2012-09-30 | $22.93B | $71.0M | +0.31% |
| Q2 2012 | 2012-06-30 | $22.75B | −$934.0M | −3.94% |
| Q1 2012 | 2012-03-31 | $23.05B | −$22.0M | −0.10% |
| Q4 2011 | 2011-12-31 | $22.20B | $248.0M | +1.13% |
| Q3 2011 | 2011-09-30 | $22.86B | $1.20B | +5.52% |
| Q2 2011 | 2011-06-30 | $23.68B | $4.36B | +22.54% |
| Q1 2011 | 2011-03-31 | $23.07B | $3.42B | +17.42% |
| Q4 2010 | 2010-12-31 | $21.95B | $2.73B | +14.18% |
| Q3 2010 | 2010-09-30 | $21.67B | $2.40B | +12.48% |
| Q2 2010 | 2010-06-30 | $19.33B | $1.51B | +8.49% |
| Q1 2010 | 2010-03-31 | $19.65B | $3.57B | +22.21% |
| Q4 2009 | 2009-12-31 | $19.22B | $2.84B | +17.36% |
| Q3 2009 | 2009-09-30 | $19.26B | — | — |
| Q2 2009 | 2009-06-30 | $17.82B | — | — |
| Q1 2009 | 2009-03-31 | $16.08B | — | — |
| Q4 2008 | 2008-12-31 | $16.38B | — | — |
Teva Pharmaceutical Industries shareholders’ equity trends
Over the last five fiscal years, Teva Pharmaceutical Industries's shareholders’ equity decreased from $10.03B to $7.91B, a change of −$2.12B. The latest reported quarter, Q2 2026, shows $7.75B.
About the metric
What shareholders’ equity means
Shareholders’ equity is the residual accounting value attributable to shareholders after liabilities are subtracted from assets. It can change through earnings, losses, dividends, share issuance, repurchases, and other comprehensive income.
Calculation and source
SEC-reported shareholders’ equity
TickerStat standardizes stockholders’ or shareholders’ equity reported in company SEC filings at each balance-sheet date. Negative equity is retained because it can be economically meaningful. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Teva Pharmaceutical Industries source filings ↗